The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Infectious Disease & AMR

University of Pittsburgh lab shows phage attacks in new light
Infectious Disease & AMR

University of Pittsburgh lab shows phage attacks in new light

MAR 8, 2023
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101
Clinical & Manufacturing

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101

JAN 24, 2023
World’s First Computational Reconstruction of a Virus in its Biological Entirety
Infectious Disease & AMR

World’s First Computational Reconstruction of a Virus in its Biological Entirety

JAN 23, 2023
IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections
Biotics and Supplements

IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections

JAN 16, 2023
Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy
Infectious Disease & AMR

Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy

DEC 21, 2022
FDA Approves First Fecal Microbiota Product
Editor's Choice

FDA Approves First Fecal Microbiota Product

DEC 1, 2022
Anti-anaerobic antibiotics associated with increased risk of mortality in critically ill patients
Infectious Disease & AMR

Anti-anaerobic antibiotics associated with increased risk of mortality in critically ill patients

OCT 19, 2022
Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives
Infectious Disease & AMR

Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives

SEP 13, 2022
New needle-free nasal vaccine shows promise for COVID-19
Infectious Disease & AMR

New needle-free nasal vaccine shows promise for COVID-19

AUG 8, 2022
Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection
Infectious Disease & AMR

Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection

JUN 8, 2022
Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages
Infectious Disease & AMR

Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages

JUN 6, 2022